Ocular aspects of myasthenia gravis

被引:73
作者
Barton, JJS
Fouladvand, M
机构
[1] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Neurol,Human Vis & Eye Movement Lab, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Opthalmol,Human Vis & Eye Movement Lab, Boston, MA 02215 USA
[3] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA
关键词
ocular myasthenia; autoimmune disorder; diplopia; ptosis;
D O I
10.1055/s-2000-6829
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Ocular myasthenia gravis is a not uncommon autoimmune disorder causing diplopia, ptosis, and weakness of lid closure. The predilection of myasthenia for the ocular muscles may be related to differences between limb and extraocular muscles in either physiological function or antigenicity. Clinically ocular myasthenia can mimic any form of pupil-sparing ocular motility disorder. Dynamic abnormalities of myasthenic eye movements may reflect the primary hallmarks of the disease, which are fatigability and variability in strength, or secondary adaptive effects by the central nervous system, Tests to confirm the diagnosis include edrophonium challenge, repetitive nerve stimulation, single-fiber electromyography (EMG) of the frontalis, and assays for antibody directed against the acetylcholine receptor: all are less sensitive for ocular myasthenia than for generalized myasthenia. There is a higher incidence of other autoimmune conditions in myasthenia, notably thymoma and thyroid dysfunction. The differential diagnosis includes other diseases of the neuromuscular junction, such as Lambert-Eaton syndrome and botulism. Treatment consists of symptomatic use of acetylcholinesterase inhibitors and immunosuppression with steroids or azathioprine. Between 50 and 70% of patients with ocular myasthenia will eventually develop generalized disease: there is some retrospective data that steroids or azathioprine may reduce this by about 75%. The role of thymectomy in ocular myasthenia remains unclear.
引用
收藏
页码:7 / 20
页数:14
相关论文
共 134 条
[1]  
AARLI JA, 1978, ACTA NEUROL SCAND, V58, P121
[2]   MYASTHENIA-GRAVIS - ANALOG-COMPUTER MODEL [J].
ABEL, LA ;
DELLOSSO, LF ;
SCHMIDT, D ;
DAROFF, RB .
EXPERIMENTAL NEUROLOGY, 1980, 68 (02) :378-389
[3]  
ARGOV Z, 1979, NEW ENGL J MED, V301, P409, DOI 10.1056/NEJM197908233010805
[4]   SACCADE FATIGUE AND RESPONSE TO EDROPHONIUM FOR DIAGNOSIS OF MYASTHENIA-GRAVIS [J].
BALOH, RW ;
KEESEY, JC .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1976, 274 (MAY28) :631-641
[5]   PUPILLARY ABNORMALITIES IN MYASTHENIA GRAVIS -- REPORT OF A CASE [J].
BAPTISTA, AG ;
SILVAESO.H .
NEUROLOGY, 1961, 11 (03) :210-&
[6]   Quantitative ocular tests for myasthenia gravis: a comparative review with detection theory analysis [J].
Barton, JJS .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1998, 155 (01) :104-114
[7]   EFFECTS OF EDROPHONIUM ON SACCADIC VELOCITY IN NORMAL SUBJECTS AND MYASTHENIC AND NONMYASTHENIC OCULAR PALSIES [J].
BARTON, JJS ;
HUAMAN, AG ;
SHARPE, JA .
ANNALS OF NEUROLOGY, 1994, 36 (04) :585-594
[8]   SACCADIC DURATION AND INTRASACCADIC FATIGUE IN MYASTHENIC AND NONMYASTHENIC OCULAR PALSIES [J].
BARTON, JJS ;
JAMA, A ;
SHARPE, JA .
NEUROLOGY, 1995, 45 (11) :2065-2072
[9]  
BARTON JJS, 1995, INVEST OPHTH VIS SCI, V36, P1566
[10]   THE ROLE OF THE THYMUS IN MYASTHENIA-GRAVIS - IMMUNOHISTOLOGICAL AND IMMUNOLOGICAL STUDIES IN 115 CASES [J].
BERRIH-AKNIN, S ;
MOREL, E ;
RAIMOND, F ;
SAFAR, D ;
GAUD, C ;
BINET, JP ;
LEVASSEUR, P ;
BACH, JF .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1987, 505 :50-70